1-8 of 8
Hossein Borghaei, DO, MS
Close
Sort by
Journal Articles

Low Blood Absolute CD4 Counts Is Associated with Inferior Progression Free Survival in Diffuse Large B-Cell Lymphoma Independent of Age and IPI

Tahseen I. Al-Saleem, MD, Essel Dulaimi, MD, Michael M. Millenson, MD, Mitchell R. Smith, MD PhD, Julia Judd, Tianyu Li, Hossein Borghaei, DO, MS
Journal: Blood
Blood (2014) 124 (21): 5420.
https://doi.org/10.1182/blood.V124.21.5420.5420
Published: 2014
Journal Articles

Phase I Trial of Combination Therapy with 90 y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin's Lymphoma, Final Report.

Hossein Borghaei, DO, MS, Russell J. Schilder, MD, Samuel Litwin, PhD, Michael Millenson, MD, Adam D Cohen, MD, Linda Thibodeau, RN, Mitchell R Smith, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 2753.
https://doi.org/10.1182/blood.V120.21.2753.2753
Published: 2012
Journal Articles

CNTO 328, a Monoclonal Antibody to Interleukin-6, Is Active as a Single Agent in Castleman’s Disease: Preliminary Results of a Phase I Study.

Frits Van Rhee, MD, PhD, Luis Fayad, MD, Peter Voorhees, MD, Richard R Furman, MD, Hossein Borghaei, DO, MS, Sagar Lonial, MD, Lubomir Sokol, MD, PhD, Julie Crawford, BS, Mark Cornfeld, MD, MPH, Ming Qi, MD, PhD, Jennifer Herring, RN, Xiang Qin, MS, Razelle Kurzrock, MD
Journal: Blood
Blood (2008) 112 (11): 1008.
https://doi.org/10.1182/blood.V112.11.1008.1008
Published: 2008
Journal Articles

A Phase I Study of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody in Patients with B-Cell Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Castleman’s Disease.

Razelle Kurzrock, MD, Luis Fayad, Peter Voorhees, MD, Richard R Furman, MD, Sagar Lonial, MD, Hossein Borghaei, DO, MS, Sundar Jagannath, MD, Lubomir Sokol, MD, PhD, Mark Cornfeld, MD, MPH, Ming Qi, MD, PhD, Trina Jiao, MS, Jennifer Herring, RN, Xiang Qin, PhD, Frits van Rhee, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 1009.
https://doi.org/10.1182/blood.V112.11.1009.1009
Published: 2008
Journal Articles

CD4 Cell Count of More Than 250/Microl in the Peripheral Blood Is Associated with Improved Overall Survival in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Independent of the aaIPI

Hossein Borghaei, DO, MS, Mitchell Smith, MD, Ph.D., Michael Millenson, Tianyu Li, Danielle Shafer, DO, Tahseen I. Al-Saleem, MD
Journal: Blood
Blood (2008) 112 (11): 3775.
https://doi.org/10.1182/blood.V112.11.3775.3775
Published: 2008
Journal Articles

Phase I Trial of Combination Therapy with 90 Y Ibritumomab Tiuxetan (Zevalin) and Gemicitabine in Patients with Non-Hodgkin’s Lymphoma.

Hossein Borghaei, DO, MS, Mitchell R. Smith, MD, Ph.D., Michael Millenson, MD, Linda Thibodeau, RN, Nicole Kamiensky, Russell J. Schilder, MD
Journal: Blood
Blood (2007) 110 (11): 4485.
https://doi.org/10.1182/blood.V110.11.4485.4485
Published: 2007
Journal Articles

Phase I Trial of Combination Therapy with 90 Y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin’s Lymphoma.

Hossein Borghaei, DO, MS, Mitchell Smith, MD, Ph.D., Michael Millenson, MD, Danielle Shafer, DO, Linda Thibodeau, RN, Russell Schilder, MD
Journal: Blood
Blood (2006) 108 (11): 4710.
https://doi.org/10.1182/blood.V108.11.4710.4710
Published: 2006
Journal Articles

Rituximab-Mediated ADCC Is Augmented by Concomitant Interference with Inhibitory Self-Recognition by Human NK Cells.

Liat Binyamin, PhD, R. Katherine Alpaugh, Ph.D, Kerry S. Campbell, Ph.D, Hossein Borghaei, DO, MS, Louis M. Weiner, MD
Journal: Blood
Blood (2005) 106 (11): 2456.
https://doi.org/10.1182/blood.V106.11.2456.2456
Published: 2005